# Investment Journal

## Portfolio Decision Log

---

### 2026-02-05 | KPIT TECHNOLOGIES | HOLD + STOP-LOSS

**Position:** 110 shares @ â‚¹1,151.10 avg | Current: â‚¹967.40 | Loss: -15.96% (â‚¹20,207)

**Decision:** HOLD with stop-loss at â‚¹900 (biggest portfolio loss, needs monitoring)

**Rationale:** KPIT reported 22nd consecutive growth quarter with Q3 revenue up 9.5% but profit crashed 29% (â‚¹133 Cr from â‚¹187 Cr) due to â‚¹60 Cr labor provision and margin compression (EBIT 15.6% vs 17.2% YoY). Excluding provision, profit still down 3.5%. Margin pressure is red flag but intrinsic value â‚¹1,235 vs current â‚¹967 shows 28% undervaluation. Multiple analysts target â‚¹1,341 (39% upside). Strong ROE 23.79% and structural sector tailwinds (software-defined vehicles, AI-infused mobility, autonomous driving) support long-term case. Stock corrected 16% from buy price - not a valuation trap but margin recovery critical. Hold with protection until Q4 confirms if margin pressure temporary or structural.

**Action Taken:**
- âœ… GTT stop-loss: 110 shares at â‚¹900 (Trigger ID: 305672287)
- ðŸ“Š Monitoring: Q3 results analysis, margin trends, automotive sector, European market health

**Follow-Up Schedule:**
- ðŸ“… **February 2026**: Monitor â‚¹900 support level, watch automotive sector news
- ðŸ“… **April-May 2026**: Q4 FY26 results - CRITICAL check for EBIT margin recovery (must be >16.5%)
- ðŸ“… **July 2026**: Q1 FY27 results - Confirm margin trend direction (if >16%, upgrade; if <15%, exit)
- ðŸ“… **Quarterly**: Track European automotive OEM earnings, order book momentum, TCV wins
- ðŸŽ¯ **Price Targets**: â‚¹1,050-1,100 (3M) | â‚¹1,150-1,200 (6M) | â‚¹1,250-1,341 (12M)

**Exit Criteria:**
- âœ… Stop-loss hit at â‚¹900
- âŒ Q4 EBIT margin <15% (structural decline confirmed for 3+ quarters)
- âŒ Major client loss (>15% revenue impact) or European automotive recession
- âœ… Partial exit at â‚¹1,100-1,150 on rally if margin concerns persist

---

### 2026-02-05 | VA TECH WABAG | ACCUMULATE + STOP-LOSS

**Position:** 64 shares @ â‚¹1,243.46 avg | Current: â‚¹1,189 | Loss: -4.38% (â‚¹3,485)

**Decision:** ACCUMULATE - Buy 20 more shares at â‚¹1,150 + GTT stop-loss at â‚¹1,000

**Rationale:** VA Tech Wabag shows strong fundamentals with â‚¹16,000 Cr order book providing 3.3x EPC and 8.6x O&M revenue visibility. Recent order wins include â‚¹3,251 Cr Saudi desalination project and â‚¹600 Cr BPCL contract. Q2 FY26 showed 19% revenue growth and 21% profit growth. Multiple analysts (B&K Securities, Systematix) initiated BUY ratings with 83-89% upside potential, projecting 15.7% revenue CAGR and 23% earnings CAGR (FY25-28E) with margin expansion to 14.6%. Water infrastructure sector has structural tailwinds (rising water stress, low wastewater treatment capacity). Current 4.38% loss presents accumulation opportunity given massive order book visibility and positive sector outlook.

**Action Taken:**
- âœ… GTT BUY order: 20 shares at â‚¹1,150 (Trigger ID: 305665451)
- âœ… GTT stop-loss: 64 shares at â‚¹1,000 (Trigger ID: 305665456)
- ðŸ“Š Monitoring: Q3 results (Feb 5), order book additions, margin trends, working capital

**Follow-Up Schedule:**
- ðŸ“… **Feb 5-10, 2026**: Q3 FY26 results - Watch revenue growth (>15%), margins (>13%), new orders
- ðŸ“… **After Buy Executes**: Update stop-loss from 64 to 84 shares at â‚¹1,000 (cancel old GTT, place new)
- ðŸ“… **May 2026**: Q4 FY26 results - Full year performance and FY27 guidance
- ðŸ“… **Quarterly**: Order book updates, new wins, execution pace
- ðŸŽ¯ **Price Targets**: â‚¹1,350-1,400 (6M) | â‚¹1,500-1,600 (12M) | â‚¹1,800-2,000 (18-24M)

**Position After Buy Executes:**
- Total Shares: 84 (64 current + 20 new)
- New Average: ~â‚¹1,230 (improved from â‚¹1,243)
- Total Investment: ~â‚¹1,03,500

**Exit Criteria:**
- âœ… Stop-loss hit at â‚¹1,000 (protect capital)
- âŒ Order book growth slows significantly or major cancellations
- âŒ Margins compress below 12% for 2 consecutive quarters
- âœ… Partial exit (30-40%) at â‚¹1,500 to book profit and reduce risk
- âœ… Trail stop-loss upward as stock appreciates

---

### 2026-02-05 | INDIGO | HOLD + TRAILING STOP-LOSS

**Position:** 22 shares @ â‚¹4,726.46 avg | Current: â‚¹4,875 | Gain: +3.14% (â‚¹3,268)

**Decision:** HOLD with trailing stop-loss at â‚¹4,500 (breakeven protection)

**Rationale:** IndiGo's Q3 profit collapsed 77% to â‚¹550 Cr due to â‚¹15.5 billion exceptional charges (December operational chaos costing â‚¹5.8B, forex losses of â‚¹10.4B, and labor reform charges of â‚¹9.7B). However, core revenue grew 6.7% and most charges are one-time/non-recurring. Fleet expansion continues aggressively (440 aircraft, +57 in 2025) supporting long-term growth. Unlike Mankind's valuation trap, IndiGo's issues are operational/exceptional. Key risks: ongoing forex exposure with rupee volatility and operational efficiency. Stop-loss at â‚¹4,500 protects near breakeven while allowing recovery if Q4 shows clean profitability without exceptional items.

**Action Taken:**
- âœ… GTT stop-loss order placed at â‚¹4,500 (Trigger ID: 305631403)
- ðŸ“Š Monitoring: Forex losses trend, operational efficiency, load factor, ex-exceptional profitability

**Follow-Up Schedule:**
- ðŸ“… **April 15-30, 2026**: Q4 FY26 results - Check for forex loss continuation and operational improvements
- ðŸ“… **July 2026**: Q1 FY27 results - Assess if profitability normalizes post-exceptional items
- ðŸ“… **Monthly**: Track USD/INR forex trends (impacts aircraft lease costs)
- ðŸŽ¯ **Price Alerts**: â‚¹5,200 (reassess upside potential) | â‚¹4,500 (stop-loss trigger)

**Exit Criteria:**
- âœ… Stop-loss hit at â‚¹4,500
- âŒ Q4 shows continued forex losses >â‚¹8B or operational margins deteriorate
- âœ… Upgrade to accumulate if Q4 profit >â‚¹1,500 Cr (ex-exceptional items)

---

### 2026-02-05 | MANKIND PHARMA | HOLD + STOP-LOSS

**Position:** 100 shares @ â‚¹2,290.33 avg | Current: â‚¹2,085 | Loss: -8.96% (â‚¹20,533)

**Decision:** HOLD with strict monitoring + GTT stop-loss at â‚¹1,950 (-15%)

**Rationale:** Mankind Pharma reported mixed Q3 results with revenue growth of 11.5% but concerning EBITDA margin compression from 25.6% to 22.9%. The stock trades at a premium valuation of 45x P/E versus pharma peers (Sun: 30x, Cipla: 28x, Dr. Reddy's: 35x), raising valuation trap concerns. While revenue growth remains healthy and analyst targets suggest 18% upside to â‚¹2,460, the margin pressure needs resolution. Key watch points: Q4 margin recovery and peer performance. Stop-loss protects against further downside if fundamentals deteriorate. Will reassess if margins don't stabilize by Q1 FY27.

**Action Taken:**
- âœ… GTT stop-loss order placed at â‚¹1,950 (Trigger ID: 305578263)
- ðŸ“Š Monitoring: EBITDA margins, P/E compression, Q4 results, peer comparison

**Follow-Up Schedule:**
- ðŸ“… **April-May 2026**: Q4 FY26 results - Critical check for EBITDA margin recovery (target: >24%)
- ðŸ“… **July 2026**: Q1 FY27 results - Assess if margin compression trend reverses
- ðŸ“… **Monthly**: Compare P/E with pharma peers (Sun, Cipla, Dr. Reddy's) for valuation gap
- ðŸŽ¯ **Price Alerts**: â‚¹2,200 (reassess exit on bounce) | â‚¹2,460 (analyst target, book profit) | â‚¹1,950 (stop-loss trigger)

**Exit Criteria:**
- âœ… Stop-loss hit at â‚¹1,950
- âŒ EBITDA margins stay below 24% for 2 consecutive quarters
- âŒ P/E remains >40x while peers trade at <35x with better margins
- âœ… Partial exit at â‚¹2,200-2,300 range to reduce risk exposure

---

